Lantheus Holdings Inc. (LNTH) is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight, and Follow disease in order to deliver better patient outcomes. The company recently reported impressive financial results for its fiscal period ending December 31, 2023. LNTHns net income turned positive, with earnings of $1.45 per share compared to a loss of $1.61 per share the previous year. Although income faded by -22.68% from $1.88 per share in the preceding reporting period, the company?s revenue experienced a significant increase of 34.557% to $354.11 million from $263.17 million in the same period a year before. Sequentially, revenue advanced by 11.023% from $318.95 million.LNTHns top-line growth in the fourth quarter of 2023 is consistent with its peers in the In Vitro and In Vivo Diagnostic Substances sector, which reported an overall 5.74% revenue increase in the same period. It is worth noting that Lantheus Holdings Inc. achieved net profits of $103.38 million in the fiscal period ending December 31, 2023, a significant improvement compared to a net shortfall of $-119.185 million in the same period the previous year. The company also highlighted its improving profit margins, with https://csimarket.com/stocks/news.php?code=LNTH&date=2024-02-22165556&utm_source=dlvr.it&utm_medium=tumblr
